Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
3(43%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
4
57%
Ph early_phase_1
1
14%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(3)
Completed(4)

Detailed Status

Completed4
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (14.3%)
Phase 12 (28.6%)
Phase 24 (57.1%)

Trials by Status

recruiting229%
completed457%
active_not_recruiting114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_2

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
recruitingphase_2

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

NCT05417165
active_not_recruitingphase_2

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01351896
completedearly_phase_1

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01239875
completedphase_1

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

NCT00046852
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05183854Phase 2

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

Recruiting
NCT05417165Phase 2

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Recruiting
NCT01351896Phase 2

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active Not Recruiting
NCT01239875Early Phase 1

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma

Completed
NCT00046852Phase 1

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Completed
NCT00445484Phase 2

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT00499577Phase 1

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7